Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (15188)	5/5/1999 3:46:00 PM
From: Ga Bard	Read Replies (1) \| Respond to of 25711

MMTS getting volume and UT on tiny volume at that. :-) ... GB

To: Joe Copia who wrote (15188)	5/6/1999 8:34:00 AM
From: Witold	Respond to of 25711

Joe, CYTO news alert: first profitable quarter in its history!! CYTO (Biotech, cancer pain and diagnostic drug) News Alert! The company has turned around (with the efforts of new management) and now has shown first profitable quarter in its history. Today they will have live conference call broadcast on the Internet. This also shows that they are trying hard to advertise their US and Canada - approved drugs. biz.yahoo.com biz.yahoo.com Morning news - 1st profitable quarter in its history. $0.03 per share comparing to the loss of 0.08 last year. The company efforts to re-structure, cut down ineffective parts of the business and increase sale have finally paid off. A 50% - 100% price jump is possible today from the low $1 1/8 base-line levels. ".....The Company also reported that it is now directing its efforts toward longer range development of the business. Highlights of the first quarter included: * Reorientation of sales efforts for the Company's ProstaScint prostate cancer imaging agent, migrating the field force from a technical support role to include direct selling efforts, together with a realignment of territories to focus on areas with greatest potential * Development of a widely applicable interactive internet-based training program in the use of ProstaScint, to be introduced in the second quarter * Plans for development of the Company's proprietary Prostate Specific Membrane Antigen ("PSMA") technology with emphasis on immunotherapy use in prostate and other cancers; continued emphasis on diagnostic approaches * Sale of the Company's laboratory and manufacturing facilities and implementation of a new lower cost manufacturing arrangement and production plan * Launch of the Company's Quadramet bone pain cancer product by Berlex Laboratories, Inc. on March 9 * Defined the use of OncoScint in ovarian indications, through market research and initiated active selling efforts emphasizing this indication * Plans for international marketing expansion for products approved or in the approval process in Canada and exploring European opportunities * Positioning AxCell Biosciences to achieve automation of its proteomics drug platform